SUBCLINICAL MESOTHELIOMA
Clinical trials for SUBCLINICAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new SUBCLINICAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for SUBCLINICAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug trial for rare cancer syndrome halted before starting
Disease control TerminatedThis study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdraw…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 09:42 UTC
-
New hope for rare cancer: pill may stall mesothelioma in High-Risk patients
Disease control TerminatedThis study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have very early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or improve it. About 9 participants will receive treatment and be monitored for…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:49 UTC